Takeda gives Sun Pharma, Cipla rights to commercialize gastro drug in India
Takeda gives Sun Pharma, Cipla rights to commercialize gastro drug in India
BENGALURU, June 21 (Reuters) – Japan’s Takeda Pharmaceutical (4502.T) gave India’s Sun Pharmaceutical (SUN.NS) and Cipla (CIPL.NS) the rights to commercialize the gastrointestinal drug Vonoprazan in the country.
The drug, which is sold in the form of tablets under the brand name ‘Voltapraz’, blocks a key step in the production of stomach acid, Sun Pharma said on Friday. Cipla announced the agreement late on Thursday.
Takeda has granted both drugmakers non-exclusive patent licensing rights for the drug.
